Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
复制标题
DOI：
10.1200/jco.2017.77.0446
复制
发表时间：
2018-04-01
影响因子：
45.3
通讯作者：
Burstein, Harold
中科院分区：
文献类型：
--
作者：
Heymach, John;Krilov, Lada;Burstein, Harold
来自ASCO主席的信息我还记得ASCO第一次设想发表一份关于癌症护理中最具变革性的研究的年度报告的时候。在提交13份报告之后，我们所记录的进展是显著的，今年也不例外。ASCO 2018年度临床癌症进展报告中的研究强调了我们对癌症的理解以及我们针对肿瘤基因组成定制治疗的能力的令人印象深刻的进步。ASCO 2018年度进展，过继细胞免疫疗法，允许临床医生对患者自身的免疫细胞进行基因重组，以发现和攻击全身的癌细胞。嵌合抗原受体（CAR）T细胞疗法是一种过继性细胞免疫疗法，在急性淋巴细胞白血病（ALL）的年轻患者以及淋巴瘤和多发性骨髓瘤的成人患者中取得了显着的效果。研究人员也在探索其他类型的癌症的这种方法。如果没有联邦对癌症研究的大力投资，这一进展是不可能的。在ALL儿童中进行的第一项CAR T细胞治疗的临床试验部分由美国国家癌症研究所（NCI）赠款，NCI癌症研究中心的研究人员是第一个报告可能的CAR T细胞治疗多发性骨髓瘤的研究人员。这些发现是在免疫学和癌症生物学数十年研究的基础上取得的，其中大部分是由联邦资金支持的。事实上，2018年临床癌症进展报告中强调的许多进展都是由于我们国家对生物医学研究的支持。来自美国国立卫生研究院和NCI的资金帮助研究人员研究关键的患者护理问题，并解决私营企业几乎没有动力承担的重要的未满足的需求。联邦政府支持的癌症研究产生了生物医学创新，推动了新的和改进的患者治疗方法的开发和可用性。我们需要持续的联邦研究投资来加速下一代癌症治疗方法的发现。今年报告中的另一个主要趋势是治疗癌症的精准医学方法的进展。尽管精准医疗为癌症患者及其家人带来了希望，但这一希望只有在我们能够为所有患者提供这些治疗的情况下才能实现。我的总统主题是“交付发现：扩大精准医学的范围”，重点是应对这一艰巨的挑战，使任何面临癌症诊断的人都能获得新的靶向治疗。通过改善获得高质量护理的途径，利用地球仪患者治疗结果的大数据，以及开展创新的临床试验，我乐观地认为，我们将加快向更多患者提供这些最有前途的治疗方法。约翰逊，FASCOASCO总裁，2017年至2018年
A MESSAGE FROM ASCO'S PRESIDENTI remember when ASCO first conceived of publishing an annual report on the most transformative research occurring in cancer care. Thirteen reports later, the progress we have chronicled is remarkable, and this year is no different. The research featured in ASCO's Clinical Cancer Advances 2018 report underscores the impressive gains in our understanding of cancer and in our ability to tailor treatments to tumors' genetic makeup.The ASCO 2018 Advance of the Year, adoptive cell immunotherapy, allows clinicians to genetically reprogram patients' own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR) T-cell therapya type of adoptive cell immunotherapyhas led to remarkable results in young patients with acute lymphoblastic leukemia (ALL) and in adults with lymphoma and multiple myeloma. Researchers are also exploring this approach in other types of cancer.This advance would not be possible without robust federal investment in cancer research. The first clinical trial of CAR T-cell therapy in children with ALL was funded, in part, by grants from the National Cancer Institute (NCI), and researchers at the NCI Center for Cancer Research were the first to report on possible CAR T-cell therapy for multiple myeloma. These discoveries follow decades of prior research on immunology and cancer biology, much of which was supported by federal dollars.In fact, many advances that are highlighted in the 2018 Clinical Cancer Advances report were made possible thanks to our nation's support for biomedical research. Funding from the US National Institutes of Health and the NCI helps researchers pursue critical patient care questions and addresses vital, unmet needs that private industry has little incentive to take on. Federally supported cancer research generates the biomedical innovations that fuel the development and availability of new and improved treatments for patients. We need sustained federal research investment to accelerate the discovery of the next generation of cancer treatments.Another major trend in this year's report is progress in precision medicine approaches to treat cancer. Although precision medicine offers promise to people with cancer and their families, that promise is only as good as our ability to make these treatments available to all patients. My presidential theme, Delivering Discoveries: Expanding the Reach of Precision Medicine, focuses on tackling this formidable challenge so that new targeted therapies are accessible to anyone who faces a cancer diagnosis. By improving access to high-quality care, harnessing big data on patient outcomes from across the globe, and pursuing innovative clinical trials, I am optimistic that we will speed the delivery of these most promising treatments to more patients.Sincerely,Bruce E. Johnson, FASCOASCO President, 2017 to 2018